Supplementary Appendix S2. Primary and Secondary Endpoint Definitions
Primary Endpoint: The proportion of patients with an HbA1c <7.0% at Day 365 AND free of severe hypoglycemic events from Day 28 to Day 365 inclusive following the first islet transplant, with the day of transplant designated Day 0.
Severe hypoglycemic event (SHE):
An event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, in which the patient was unable to treat him/herself and which was associated with either a blood glucose level <54 mg/dL (3.0 mmol/L) or prompt recovery after oral carbohydrate, IV glucose, or glucagon administration.
Insulin Independence: Islet transplant recipients will be considered insulin-independent with full islet graft function if they are able to titrate off insulin therapy for at least 1 week and all of the following criteria are met:
• One HbA1c level, one fasting serum glucose level, and a Mixed Meal Tolerance Test are documented within the visit window (e.g. 70-80 days at Day 75) and 7 consecutive days of blood sugar and insulin readings are documented within +/-7 days of the visit window (e.g. 63 -87 days at Day 75); • HbA1c <7.0% or a ≥2.5% decrease from baseline;
• Fasting capillary glucose level should not exceed 140 mg/dL (7.8 mmol/L) more than three times in the 7 consecutive days (fasting is defined as 1st blood sugar reading of the day not noted as post-prandial or bedtime); • Post-prandial serum glucose ≤ 180 mg/dL (10.0 mmol/L) at 90 minutes during the MMTT; • Fasting serum glucose level ≤126 mg/dL (7.0 mmol/L): if the fasting serum glucose level is >126 mg/dL (7.0 mmol/L), it must be confirmed in an additional one out of two measurements; • At least one MMTT fasting or stimulated c-peptide ≥0.5 ng/ml. 
Supplementary Appendix S4. CONSORT Diagram
Three hundred forty-one patients signed written informed consent to participate in a screening/baseline study. Seventy of these patients terminated their participation before completing the screening process. One hundred thirty-eight patients completed screening but were considered screen failures. One hundred thirty-three patients were screening eligible. They were placed on the waitlist to receive a compatible pancreas suitable for islet isolation. When a pancreas became available for a waitlisted patient, that patient was randomized to participate in Protocol CIT-07 or a CIT Phase 2 pilot study. Forty-eight patients were randomized to CIT-07. All 48 patients randomized to Protocol CIT-07 received one or more PHPI transplant(s).
Forty-five patients remained enrolled in Protocol CIT-07 through evaluation of the primary end point at one year post-initial transplant; 3 were lost to follow-up. Forty-two of the 45 remaining patients achieved success on the primary end point. The Bonferroni method was used to adjust the level of significance for these three comparisons in order to preserve the overall Type 1 error rate of 0.05. The Bonferroni method was used to adjust the level of significance for these three comparisons in order to preserve the overall Type 1 error rate of 0.05.
The adjusted p-values for these three tests are less than 0.0003. 
Supplementary Appendix S13. Reasons for Failure to Complete 2 Years of Follow-Up in CIT-07

Patient* Comments
1
Consented under an early version of the CIT-07 protocol that called for only one year of follow-up.
3
Withdrew consent due to frequency of study visits.
5
6
Received an islet transplant in a study outside of CIT.
41
Started taking Januvia, a study prohibited medication; withdrawn from study.
*Patient numbers in this table are not in temporal order
Supplementary Appendix S14. Serious Adverse Event Listing 
System Organ Class Preferred Term Patient Description
Cardiac disorders Atrial flutter 38 The patient experienced asymptomatic, irregular tachycardia (HR=108) and subsequently was diagnosed with atrial flutter on the 2nd day after initial islet transplant. The event was evaluated as being possibly related to the islet infusion procedure or possibly related to the immunosuppressive and conditioning regimen. The patient was treated with cardioversion and four weeks of coumadin anticoagulation. The event did not recur and resolved without sequelae on the following day. Gastrointestinal disorders
Abdominal pain upper 40
The patient reported epigastric pain 8 days after initial islet transplantation. A multisystem workup was negative except for a markedly elevated sirolimus level (25), with pain resolving with resolution of elevated sirolimus levels. The event was attributed to elevated sirolimus levels and/or late onset pain associated with the islet infusion procedure. The event resolved without sequelae on the following day.
Gastrointestinal disorders Vomiting 18
The patient experienced vomiting and headache on day 5 after the initial islet transplant. The event was attributed to the islet infusion procedure and/or immunosuppression, and/or the patient's established history of migraine. The event resolved without sequelae on the following day. Gastrointestinal disorders Vomiting 28
The patient reported worsening nausea and vomiting on 3 days after initial islet transplantation. The patient was admitted for supportive care; immunosuppressant doses were reduced, with subsequent resolution of symptoms. The event was attributed to immunosuppression. The event resolved without sequelae two days later. General disorders and administration site conditions
Adverse drug reaction 45
During pre-transplant conditioning, the patient developed urticaria on the face, abdomen and back. The event was attributed to thymoglobulin. The patient received a 7 day course of prednisone, and the planned islet transplant was cancelled; the patient subsequently received a transplant approximately 6 months later. The event resolved without sequelae approximately six weeks after onset.
General disorders and administration site conditions
Chest discomfort 16 Approximately 12 and 17 months after islet transplantation procedures, the patient reported chest pressure radiating across the upper chest with dyspnea and palpitation. During the subsequent hospitalization, the workup was negative for acute MI or cardiac ischemia. Orthostatic hypotension was newly diagnosed. The event was not attributed to the islet product or infusion and not attributed to the IS regimen or infectious prophylaxis. The event resolved one day later.
General disorders and administration site conditions
Infusion site haemorrhage 27
The patient complained of nausea and upper abdominal pain one day after the islet transplant, performed via percutaneous access to the portal vein. The workup led to laprascopic evacuation of intra-abdominal blood. The event was attributed to the islet infusion procedure. The event resolved without sequelae.
System Organ Class Preferred Term Patient Description
General disorders and administration site conditions Non-cardiac chest  pain   11 Approximately 2 months and 6 months after islet transplantation procedures, and one day after a follow-up visit, the patient was hospitalized with complaints of chest pain and palpitations. Clinical evaluation directed at possible cardiac ischemia or PE etiologies was negative. Metoprolol was started to treat a pre-existing history of episodic palpitations. No specific etiology was uncovered. The event was not attributed to the islet product or infusion and not attributed to the IS regimen or infectious prophylaxis. The event resolved without sequelae after one day. General disorders and administration site conditions
Non-cardiac chest pain 29
Approximately 4 months and 6 months after islet transplantation procedures, the patient experienced sudden left subscapular pain, radiating to the anterior chest, exacerbated by breathing, and was admitted with concern for cardiac ischemic or PE etiologies, but the workup was negative. No specific etiology was found. The event was not attributed to the transplant or the immunosuppressive or infectious prophylaxis. The event resolved without sequelae after 2 weeks.
Immune system disorders
Cytokine release syndrome 31 Prior to this event, the patient experienced multiple symptoms during pre-transplant ATG, including diaphoresis, flushing, headache, emesis. Post-transplant ATG doses were reduced and these were tolerated. Heparin therapy was also discontinued due to thromocytopenia. On day 5 after transplant, several hours prior to a scheduled ATG infusion, the patient had the onset of headache nausea, diaphoresis, photosensitivity and difficulty speaking while at home. The scheduled ATG dose was not given, investigations/consultations including head CT and MRA were negative, and symptoms resolved with supportive care. The event was attributed to the immunosuppressive conditioning regimen. The event resolved one day later.
Immune system disorders Food allergy 29 Approximately 11 months and 14 months after islet transplantations, the patient reported acute difficulty breathing after eating shrimp. The patient was seen in a local ER and was administered two doses of epinephrine. Subsequent outpatient allergy consultation diagnosed an allergy to shrimp tropomyosin. The patient was advised to avoid crab and lobster also. The event was not attributed as related to the islets or the procedure, nor to the immunosuppression or infection prophylaxis. The event was reported as resolved approximately three weeks later without sequelae.
System Organ Class Preferred Term Patient Description
Immune system disorders Serum sickness 45 Subsequent to pre-transplantation conditioning, the patient experienced a persistent rash, recurring after the completion of a 7 day course of prednisone for an allergic reaction attributed to thymoglobulin. Low levels of complement C3 and C4 were interpreted as consistent with serum sickness. A longer tapering course of prednisone was given. The event was attributed to the immunosuppressive conditioning regimen; the scheduled islet infusion had already been cancelled. The event was reported as resolved without sequelae approximately 6 weeks after onset.
Infections and infestations
Appendicitis 29 17 months after initial islet transplant and 15 months after 2nd islet transplant, the patient presented with nausea, RUQ pain with rebound. After abdominal ultrasound, the patient had an uncomplicated laproscopic appendectomy. The event was not attributed to the transplanted islets or the procedure; the event was not attributed to the immunosuppressive regimen or anti-infective prophylaxis. The event was reported as resolved without sequelae approximately 3 weeks after onset.
Gastroenteritis 18
The patient presented with headache, nausea and vomiting, 70 days after initial islet transplant. The event was not attributed to the islets or procedure, and not attributed to the immunosuppression or infection prophylaxis. The event was attributed to the patient's pre-existing history of migraine. The event was reported as resolved without sequelae 2 days later.
Infections and infestations
Gastroenteritis 30 Approximately 4 months and 7 months after islet transplantation procedures, the patient developed acute nausea vomiting and diarrhea shortly after a salmon lunch. The symptoms resolved with hospitalization, hydration, and supportive care. The event was considered to be non-infectious, and not attributed to the islets or the procedure, nor associated with the immunosuppression or anti-infection prophylaxis. The event was reported as resolved without sequelae one day after onset.
System Organ Class Preferred Term Patient Description
Infections and infestations
Pneumocystis jiroveci pneumonia 20
Approximately 620 days after the patient's only islet transplantation, the patient was transferred to the transplant hospital after 3 days local hospitalization marked by progressive dyspnea, hypoxia, fever, and pulmonary infiltrates not responding to antibacterial therapy. BAL cytology revealed pneumocystis. The patient was not on Bactrim due to rash, and started treatment with clindamycin + primaquin + prednisone which was modified to bactrim + prednisone after desensitization. The patient had a supplemental O2 requirement (peak 10L NC) that slowly improved over ~10 days. Due to concerns about hyperkalemia, the patient was subsequently placed on atovaquone treatment almost two weeks into the 21 day treatment course. The patient was on insulin but was able to discontinue supplemental insulin at the completion of the prednisone course. The patient remained on atovoqone prophylaxis with uncomplicated recovery after completing pneumocystis therapy. The event was attributed to the immunosuppressive regimen. The event resolved without sequelae 1 month after onset.
Infections and infestations
Pyelonephritis 27 Approximately 540 days after the patient's only islet transplantation, the patient presented with acute dysuria and fever and was diagnosed with a urinary tract infection. Levofloxacin was given. After initial symptomatic improvement, the patient developed chills and flank pain and was admitted to the hospital. New cultures and imaging were negative. The antibiotic regimen was changed to cefepime and subsequently oral cefpodoxime for a 14 day course. The event was attributed to immunosuppressive therapy. The event resolved without sequelae.
Injury, poisoning and procedural complications
Drug toxicity 41 The patient presented with vomiting and elevated transaminases 6 days after transplant. The symptoms were attributed to sirolimus, due to an elevated (nontrough) sirolimus level. Dosing was adjusted during a three day hospitalization. The event was not attributed to the procedure or the islet product, but was attributed to the immunosuppressive regimen. The event resolved without sequelae three days after onset. Injury, poisoning and procedural complications Hepatic haematoma 11
Slightly less than 2 months after a second islet transplant and 5 months after initial islet transplant, the patient was in a motor vehicle accident: the car the patient was driving was hit by another car on the driver's side. The patient did not have any loss of consciousness or hypoglycemia; the patient needed to be extracted from the car. Emergency department evaluation led to a radiographic diagnosis of subcapsular liver hematoma. The patient was hospitalized for observation for 2 days, was clinically stable, and was discharged without additional intervention. The event was not attributed to either the procedure/islet infusion and not attributed to immunosuppression/infection prophylaxis. The event resolved without sequelae three days after onset.
System Organ Class Preferred Term Patient Description
Injury, poisoning and procedural complications
Hip fracture 28 The patient tripped on a sticky floor and fell. X-rays disclosed hip fracture. The patient underwent surgical treatment with no postoperative complications. The event was not attributed to the procedure/islet infusion and not attributed to the immunosuppression/infection prophylaxis. The resolved without sequelae three days after onset. Injury, poisoning and procedural complications Medication error 42 A medication error led to administration of an incorrect, very high insulin dose via intravenous drip infusion (250 units per hour for approx 35 minutes) during hospitalization prior to transplant. The blood glucose dropped as low as 31. The patient received multiple ampules of D50; the episode was fully resolved more than 4 hours prior to transplant procedure. The event was not attributed to the procedure/islet infusion and not attributed to the immunosuppression. The event resolved without sequelae on the day of onset.
Post procedural complication 26
The patient received a second transplant which was performed percutaneously with ultrasound and fluoroscopic guidance, with gelfoam used to seal the catheter tract. The patient's hemoglobinwas stable (11g/dL) until 9 days after the procedure, at which time the patient reported acute onset of severe pain and nausea and vomiting. A local emergency department provider prescribed outpatient antiemetics and narcotic analgesic after noting a hemoglobin of 9 and perihepatic fluid. Patient returned to the emergency department after another acute episode of pain. At that point, the abdomen was distended and tender, with hemoglobin now down to 5. Two units of packed red cells were given and a workup revealed a large pseudoaneurysm in the left hepatic artery distribution that was successfully treated with coil embolization. The patient's anemia and subcapsular hematoma slowly resolved. The event was attributed to the islet infusion procedure, and not attributed to the immunosuppression/infectious prophylaxis. The event resolved without sequelae.
Injury, poisoning and procedural complications
Post procedural complication 37
The patient received an initial transplant via percutaneous approach and complained of right upper quadrant pain 4 hours after the procedure. Heparin was discontinued and 2 units of packed red cells were transfused. Ultrasound imaging was interpreted as consistent with a hepatic hematoma. No other treatment was required. The hemoglobin returned to normal within 15 days of transplant. The event was attributed to the islet infusion procedure, and not attributed to the immunosuppression/infection prophylaxis. The event resolved without sequelae.
System Organ Class Preferred Term Patient Description
Injury, poisoning and procedural complications Post procedural haemorrhage 46 On the day after receiving an initial transplant via percutaneous approach, the patient complained of severe upper abdominal pain. Ultrasound disclosed periportal and pelvic fluid collections, accompanied by a serial decrease in hemoglobin. On the next day, laparoscopy was performed with evacuation of clot and a collection of bloody fluid, and hemostasis of the liver surface was achieved. Two units of packed red cells were transfused. The event was attributed to the islet infusion procedure, and not attributed to the immunosuppression/infection prophylaxis. The event resolved without sequelae.
Post procedural haemorrhage 30
This event occurred during a second islet transplant approximately 4 months after initial islet transplant. Transplant access was performed in interventional radiology with hemorrhage noted upon withdrawal of the intraportal catheter, despite use of the gelfoam pledget. The transplant surgeons performed emergent exploratory laparatomy with coagulation of the puncture site and evacuation of 1000 ml of hemoperitoneum. Protocol-scheduled heparin was not started; 3 units of packed red cells and 1 unit of fresh frozen plasma were administered. The event was attributed to the islet infusion procedure, and not attributed to the immunosuppression/infection prophylaxis. The event resolved without sequelae.
Investigations
Immunosuppressant drug level increased 4
The patient had elevated tacrolimus and sirolimus levels 4 days after transplant, without symptoms. Both drugs were held and doses subsequently adjusted. The event was not attributed to the islet infusion procedure, but was attributed to the immunosuppression treatment. The event resolved without sequelae.
Metabolism and nutrition disorders
Hypoglycaemic unconsciousness 43 Approximately 11 months after the patient's only islet transplantation, this patient remained on insulin pump therapy. The patient awoke with no clearly recalled symptoms, but checked a BG, which was 49. The patient ate cookies and then has no clear recollection of events until she awakened on the kitchen floor. The patient called a friend who arrived to assist several minutes later. The patient was advised to adjust/lower the insulin boluses. The event was not attributed to the islet infusion procedure, and not attributed to immunosuppression. The event resolved without sequelae.
